Loading...
Loading...
SPRO| Name | Value |
|---|---|
| Revenues | 7.8M |
| Cost of Revenue | -5.7M |
| Gross Profit | 13.5M |
| Operating Expense | 26.4M |
| Operating I/L | -18.6M |
| Other Income/Expense | 1.2M |
| Interest Income | 1.2M |
| Pretax | -17.4M |
| Income Tax Expense | -0.3M |
| Net Income/Loss | -17.7M |
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in developing and commercializing treatments for multi-drug resistant bacterial infections and rare diseases. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic for complicated urinary tract infections; SPR206, an IV-administered agent for MDR Gram-negative bacterial infections; and SPR720, an oral antibiotic for non-tuberculous mycobacterial pulmonary disease. Spero has license and collaboration agreements with Meiji Seika Pharma Co., Ltd., Everest Medicines, Bill & Melinda Gates Medical Research Institute, and Vertex Pharmaceuticals Incorporated to support the development and commercialization of its products.
